| MORPHOSYS AG O.N. | 84.02 / -2.93% |
| Date/Time | 02/26 / 08:09 |
| Chg. / Chg.(%) | -2.54 / -2.93% |
| Bid | 84.02 / 90 |
| Ask | 84.58 / 89 |
| Open | 84.02 |
| Previous Close | 86.56 |
| High | 84.02 |
| Low | 84.02 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Hamburg |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 84.580 |  |
528 |
| München | 84.54 |  |
100 |
| gettex | 84.580 | |
10 |
| Frankfurt | 84.0400 | |
0 |
| Hannover | 84.02 | |
0 |
| Berlin | 84.02 | |
0 |
| Hamburg | 84.02 | |
0 |
| Düsseldorf | 84.08 | |
0 |
| Lang & Schwa.. | 83.940 | |
|
| Stuttgart | 84.080 | |
|
| Xetra | 85.36 | |
138,658 |
| Cboe Europe .. | 85.16 | |
28,145 |
| Turquoise | 85.18 | |
13,148 |
| London Inter.. | 84.88 | 5,662 | |
| Vienna Globa.. | 85.16 | |
80 |
| Cboe Europe .. | 85.56 | 495 | |
| Cboe Europe .. | 85.92 | 22 | |
| Nasdaq Other.. | 113.1500 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time